Lung Cancer Therapeutics Market By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Combination Therapy), By Drug Class (Tyrosine Kinase Inhibitors (TKIs), Immune Checkpoint Inhibitors, Anti-Angiogenesis Agents, Cytotoxic Agents), By Cancer Type (Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), By Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies), and By Region; Global Insights & Forecast (2024 ? 2030)

As per Intent Market Research, the Lung Cancer Therapeutics Market was valued at USD 31.5 Billion in 2024-e and will surpass USD 62.8 Billion by 2030; growing at a CAGR of 12.2% during 2025-2030.

The lung cancer therapeutics market is experiencing robust growth, driven by the increasing prevalence of lung cancer, advancements in treatment modalities, and rising awareness about early diagnosis. Lung cancer, a leading cause of cancer-related deaths globally, has spurred significant investment in novel therapies, particularly targeted and immunotherapies, which promise better patient outcomes. With the continued integration of advanced drug classes and combination therapies, the market remains poised for sustained expansion.

Targeted Therapy Segment is Largest Owing to Precision Medicine Advancements

Targeted therapy leads the therapy type segment due to its ability to address specific genetic mutations such as EGFR, ALK, and ROS1 in lung cancer. These therapies are tailored to the molecular profile of tumors, ensuring better efficacy and fewer side effects compared to traditional methods. Drugs like Tagrisso (AstraZeneca) and Xalkori (Pfizer) have set benchmarks in this domain.

The rising adoption of companion diagnostics has further accelerated the uptake of targeted therapies. With continuous R&D efforts to identify new genetic targets, the segment is expected to maintain its dominance, providing personalized treatment solutions for patients worldwide.

Immune Checkpoint Inhibitors are Fastest Growing Owing to Expanding Applications

Within the drug class segment, immune checkpoint inhibitors are witnessing the fastest growth. These therapies, such as Keytruda (Merck) and Opdivo (Bristol-Myers Squibb), enhance the immune system's ability to attack cancer cells by targeting PD-1/PD-L1 or CTLA-4 pathways.

Their success in treating advanced and metastatic lung cancer, coupled with approvals for first-line treatment, has significantly expanded their market share. Ongoing clinical trials exploring new combinations and expanded indications are expected to further drive growth in this promising subsegment.

Non-Small Cell Lung Cancer (NSCLC) Segment is Largest Owing to High Prevalence

Non-small cell lung cancer (NSCLC) accounts for the largest share in the cancer type segment, representing approximately 85% of all lung cancer cases. The wide availability of treatment options, including chemotherapy, targeted therapy, and immunotherapy, has contributed to this dominance.

Recent advancements, such as the development of therapies targeting KRAS mutations, have further strengthened the treatment landscape for NSCLC. The introduction of combination regimens is expected to improve patient outcomes and sustain the segment's leadership in the market.

Online Pharmacies are Fastest Growing Owing to Rising Digital Adoption

Among distribution channels, online pharmacies are growing at the fastest rate, driven by the increasing adoption of digital healthcare platforms and the convenience they offer. These channels enable patients to access life-saving medications remotely, particularly in underserved regions.

The COVID-19 pandemic accelerated the shift toward online pharmacy usage. Enhanced regulatory frameworks and improved logistics networks are expected to sustain this growth, making online pharmacies an essential part of the lung cancer therapeutic ecosystem.

Asia-Pacific is the Fastest Growing Region Owing to Expanding Healthcare Access

Asia-Pacific is emerging as the fastest-growing region in the lung cancer therapeutics market. The region's growth is attributed to a rising incidence of lung cancer, increasing healthcare expenditure, and improved access to advanced treatments. Countries like China and India are investing heavily in healthcare infrastructure and cancer awareness campaigns.

Additionally, the availability of cost-effective generic drugs and the growing adoption of innovative therapies are contributing to the market's expansion in this region. Favorable government policies and initiatives to promote early cancer detection are further enhancing growth prospects.

Leading Companies and Competitive Landscape

The lung cancer therapeutics market is highly competitive, with leading companies such as AstraZeneca, Merck, Roche, and Bristol-Myers Squibb driving innovation. These players focus on expanding their portfolios through strategic collaborations, acquisitions, and investments in R&D. For instance, partnerships between pharmaceutical giants and biotechnology firms have accelerated the development of novel therapies.

The competitive landscape is characterized by the rapid approval of groundbreaking treatments and the introduction of biosimilars and generics, making therapies more accessible globally. With an emphasis on addressing unmet clinical needs, the market is set to witness sustained innovation and growth in the coming years.

Recent Developments:

• In late 2024, AstraZeneca and Daiichi Sankyo announced the global launch of Enhertu, a HER2-directed therapy targeting NSCLC.
• Merck received FDA approval in October 2024 for expanding Keytruda to include first-line treatment for metastatic NSCLC with high PD-L1 expression.
• Roche completed the acquisition of Blueprint Medicines' lung cancer pipeline in August 2024, enhancing its targeted therapy offerings.
• Pfizer and BioNTech announced a partnership in 2024 to develop mRNA-based personalized cancer vaccines for lung cancer.
• In November 2024, BMS launched a combination of Opdivo and chemotherapy for first-line treatment of advanced NSCLC in several European countries.

List of Leading Companies:

• AstraZeneca
• Pfizer Inc.
• Merck & Co., Inc.
• Roche Holding AG
• Bristol-Myers Squibb Company
• Novartis AG
• Eli Lilly and Company
• GlaxoSmithKline plc
• Bayer AG
• Sanofi
• AbbVie Inc.
• Johnson & Johnson
• Amgen Inc.
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim

Report Scope: